EN | RU
EN | RU

Help Support

Back

Effect of age on central effects of Methylnaltrexone on Opioid-Induced Constipation

Effect of age on central effects of Methylnaltrexone on Opioid-Induced Constipation Effect of age on central effects of Methylnaltrexone on Opioid-Induced Constipation
Effect of age on central effects of Methylnaltrexone on Opioid-Induced Constipation Effect of age on central effects of Methylnaltrexone on Opioid-Induced Constipation

To study if the opioid analgesia is impaired in older population who were given methylnaltrexone for the management of OIC.

See All

Key take away

Age-related changes in blood-brain barrier permeability may cause methylnaltrexone's (peripherally acting µ-opioid receptor antagonist) restricted diffusion and modify opioid-induced central pain-relieving consequences. As per the results of this study, there is no affect of age on the safety and effectiveness of methylnaltrexone for opioid-induced constipation (OIC).

Background

To study if the opioid analgesia is impaired in older population who were given methylnaltrexone for the management of OIC.

Method

Total of 1627 patients (<65 years and ≥65 years) diagnosed with OIC who used opioids for pain relief and who had terminal illness or chronic nonmalignant pain were included. Pain intensity scores, symptoms of opioid withdrawal, adverse events linked with therapy, and rescue-free laxation (RFL) in 4 hours of therapy were the study endpoints.

Result

All in all, 1323 patients were aged < 65 years in which 908 patients were in methylnaltrexone and 415 on placebo. In the same way, 304 patients were aged ≥ 65 years which 171 patients on methylnaltrexone and 133 patients on placebo.

All the groups had nonsignificant pain intensity score decreases. No statistical significant differences were found from starting point of the study in methylnaltrexone or placebo groups, in the older patients. Pain in the abdomen, flatulence, and nausea were commonly described adverse events linked with therapy. Irrespective of age, the adverse events associated with opioid withdrawal waned with the second dose than the first dose and were similar with placebo. The RFL response in 4 hours of methylnaltrexone usage increased significantly in both age groups relative to the placebo.

Conclusion

The use of Methylnaltrexone did not adversely affect opioid withdrawal effects, pain control , or adverse events while offering effective RFL, irrespective of age. 

Source:

Drugs & Aging

Article:

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation

Authors:

Solomon S Liao et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en ua
Try: